Levosulpiride and racemic sulpiride in non-ulcer dyspepsia: Results of a randomized clinical study

T. Tosi, E. Masci, D. Ceppodomo, P. A. Testoni

Research output: Contribution to journalArticle

Abstract

Using racemic sulpiride as a reference drug, we assessed the usefulness of levosulpiride (the levo-isomer of sulpiride) in the management of non-ulcer dyspepsia. In this double-blind, randomized study, 50 patients with non-ulcer dyspepsia received 25 mg of levosulpiride or 50 mg of racemic sulpiride three times daily for 30 days. Symptomatic improvement was evaluated by interview at the end of the study. Globally, a good or excellent result was obtained in both groups (P <0.01) with no statistical difference. Levosulpiride markedly reduced the severity of anorexia, nausea, postprandial fullness, belching, and epigastric pain without significant side effects. The results suggest that levosulpiride, at 25 mg TID, is effective in the treatment of chronic functional dyspepsia.

Original languageEnglish
Pages (from-to)787-791
Number of pages5
JournalCurrent Therapeutic Research
Volume51
Issue number6
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Levosulpiride and racemic sulpiride in non-ulcer dyspepsia: Results of a randomized clinical study'. Together they form a unique fingerprint.

  • Cite this